Is solifenacin succinate a safe and effective treatment for overactive bladder syndrome?

2005 ◽  
Vol 2 (2) ◽  
pp. 82-83
Author(s):  
Roger Dmochowski
Keyword(s):  
Overactive Bladder ◽  
Effective Treatment ◽  
Overactive Bladder Syndrome ◽  
Solifenacin Succinate

scholarly journals Comparison of the efficacy of Solifenacin Succinate and Tolterodine for the treatment of overactive bladder syndrome

2017 ◽  
Vol 8 (2) ◽  
pp. 231-234
Author(s):  
Mohammad Monsur Hallaz ◽  
BH Nazma Yasmeen ◽  
Nadia Sultana ◽  
Mahfuza Akter ◽  
Nurul Alam Basher
Keyword(s):  
Overactive Bladder ◽  
Extended Release ◽  
Private Hospital ◽  
Overactive Bladder Syndrome ◽  
College Hospital ◽  
Medical College ◽  
Release Preparation ◽  
Solifenacin Succinate ◽  
Randomized Control ◽  
New Generation

Background : Overactive Bladder Syndrome(OAB) is not an uncommon problem. Although exact incidence of this disease in our country is not known but a significant number of people suffering from this disease seek treatment at the Urology department of different hospitals. At present two common antimuscarinic drug Solifenacin Succinate and Tolterodine are available in our country for the treatment of OAB.Objective : To compare the efficacy of Solifenacin Succinate and Tolterodine to treat OAB.Methodology : This hospital based randomized control trial was conducted in the Department of Urology, Dhaka Medical College Hospital, Dhaka and a private hospital from January 2009 to December 2010 to compare the efficacy of two new generation antimuscarinics, Solifenacin succinate and Tolterodine at their recommended doses for the treatment of OAB.Results : After 3 months of treatment it has clearly shown that Solifenacin is more effective in reducing OAB symptoms compared with extended release preparation of Tolterodine. This include statistically significant reduction in episodes of frequency, urgency, urge incontinence, nocturia and significant improvement of voided volume.Northern International Medical College Journal Vol.8(2) January 2017: 231-234

scholarly journals Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial

2010 ◽  
Vol 4 ◽  
pp. CMU.S4960 ◽  
Author(s):  
Fred E Govier ◽  
Neila Smith ◽  
Takeshi Uchida
Keyword(s):  
Overactive Bladder ◽  
Phase Iii ◽  
Overactive Bladder Syndrome ◽  
Efficacy And Safety ◽  
Pivotal Trial ◽  
Antimuscarinic Agent ◽  
Double Blind ◽  
Solifenacin Succinate ◽  
Parallel Group ◽  
End Of Treatment

Introduction This multicenter, randomized, double-blind, parallel-group, Phase III, pivotal trial investigated the efficacy and safety of solifenacin succinate 10 mg, a once-daily (OD) oral antimuscarinic agent, in overactive bladder syndrome (OAB). Materials and methods A total of 634 adult patients with OAB symptoms were randomized to either solifenacin 10 mg (n = 318) or placebo (n = 316) OD over 12 weeks, to examine changes from baseline in micturition-, incontinence-, urgency- and nocturia-episodes/24 hours, measured using a 3-day diary. Results Solifenacin significantly reduced the mean number of micturition-, urgency- and incontinence-episodes/24 hours at end of treatment ( P < 0.001 for all versus placebo); these improvements were observed at 4 weeks, and continued over 12 weeks. Adverse events were generally mild or moderate in severity and typically anticholinergic in nature. Conclusions Solifenacin 10 mg OD was well tolerated and effective in treating major OAB symptoms, including urinary incontinence, frequency and urgency.

scholarly journals A randomized, multicenter, controlled study, comparing efficacy and safety of a new complementary and alternative medicine (CAM) versus Solifenacin Succinate in women with overactive bladder syndrome

2017 ◽  
Vol 89 (4) ◽  
pp. 296 ◽  
Author(s):  
Carlo Vecchioli-Scaldazza ◽  
Carolina Morosetti ◽  
Serena Maruccia ◽  
Stefano Casellato ◽  
Wilma Rociola ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Alternative Medicine ◽  
Complementary And Alternative Medicine ◽  
Controlled Study ◽  
Overactive Bladder Syndrome ◽  
Solifenacin Succinate ◽  
Number Of Patients ◽  
Group A ◽  
Group B ◽  
Complementary And Alternative

Introduction: To assess efficacy and tolerability of a new complementary and alternative medicine (CAM) consisting of vitamins (C and D), herbal products (cucurbita maxima, capsicum annum, polygonum capsicatum) and amino acid L-Glutammina, in the treatment of female Overactive Bladder syndrome (OAB). Materials and methods: 90 consecutive women with OAB symptoms were enrolled in this prospective, randomized, controlled study. Women were divided randomly into two groups of 45 patients each. In group A, women received Solifenacin Succinate (SS), 5 mg. once a day for 12 weeks. In group B, women received CAM, 930 mg, twice daily for 12 weeks. Women were assessed with 3-day micturition diary, Patient Perception of Intensity of Urgency Scale (PPIUS), Overactive Bladder questionnaire Short Form (OAB-q SF) and Patient Global Impression of Improvement questionnaire (PGI-I). Results: 8 patients in group A and 1 patient in group B dropped out from therapy because of side effects. A reduction in the number of daily micturitions, nocturia and episodes of urge incontinence was present with both SS and CAM with statistically highly significant differences, but CAM was significantly more effective than SS. PPIUS and OAB-q SF showed improvements with both SS and CAM with a more significant efficacy of CAM. PGI-I, demonstrated improvements in the two groups of patients with a greater satisfaction expressed by patients treated with CAM. Conclusions: the small number of patients does not permit definitive conclusions; however, the results of the research showed the greater effectiveness and tolerability of CAM.

Sign in / Sign up

Export Citation Format

Share Document